Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

20 21 Next >

Should You Give Up on Novavax? ↗

March 03, 2023

After a spectacular 2020 performance, Novavax's shares have plummeted.

Via The Motley Fool

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing ↗

March 02, 2023

The FDA made a bold move in the CRISPR gene-editing realm.

Via Investor's Business Daily

2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now ↗

February 28, 2023

These two high-yield dividend stocks are trading at bargain-basement prices.

Via The Motley Fool

Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients ↗

February 21, 2023

Via Benzinga

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

February 18, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Zoetis Stock Shows Rising Relative Strength Upgrades ↗

February 17, 2023

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Via Investor's Business Daily

Current Report: Takeda Pharmaceutical (TAK) ↗

January 23, 2023

In the past year, Takeda’s share price increased by $1.73, or about 12%.

Via Talk Markets

HUTCHMED Out Licenses Fruquintinib To Takeda Outside China ↗

January 23, 2023

Via Benzinga

Is This the Telltale Sign to Sell Novavax Stock? ↗

February 14, 2023

You won't find Novavax's latest bad news trumpeted in a press release.

Via The Motley Fool

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

February 08, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

NeurAxis: Should You Buy This IPO? ↗

February 08, 2023

As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.

Via Talk Markets

NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution ↗

February 06, 2023

As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.

Via Talk Markets

A Bullish Sign Appears On Takeda Pharmaceutical's Chart ↗

December 28, 2022

Via Benzinga

Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B ↗

December 13, 2022

Via Benzinga

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

February 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged ↗

February 02, 2023

Via Benzinga

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

February 02, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 Sorry Dividend Stocks to Sell in February Before It’s Too Late ↗

January 30, 2023

These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.

Via InvestorPlace

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce ↗

January 24, 2023

Via Benzinga

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

January 23, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

January 23, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Named Global Top Employer for Sixth Consecutive Year

January 16, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices ↗

January 14, 2023

Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...

Via Talk Markets

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

January 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study ↗

January 09, 2023

Via Benzinga

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

January 09, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

January 05, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗

December 14, 2022

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.